Les complications infectieuses liées à l’utilisation des anticorps monoclonaux chez l’homme

Rigal, E.; Gateault, Philippe; Lebranchu, Yvon; Hoarau, C.

doi:10.1051/medsci/200925121135

Cited by 5 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our finding that these drugs exhibit properties of VLA-4 allosteric antagonists provides an excellent explanation for such activity. Other VLA-4 specific competitive antagonists in some cases can cause severe immune suppression (47), and increase the risk of opportunistic infections (48). Blocking VLA-4-dependent immune cell adhesion could also explain why these types of compounds selectively affect cell-mediated component of the immune function (20).…”

Section: Discussionmentioning

confidence: 99%

Discovery of Very Late Antigen-4 (VLA-4, α4β1 Integrin) Allosteric Antagonists

Chigaev

Williams

et al. 2011

Journal of Biological Chemistry

View full text Add to dashboard Cite

Integrins are cell adhesion receptors that mediate cell-tocell, or cell-to-extracellular matrix adhesion. They represent an attractive target for treatment of multiple diseases. Two classes of small molecule integrin inhibitors have been developed. Competitive antagonists bind directly to the integrin ligand binding pocket and thus disrupt the ligand-receptor interaction. Allosteric antagonists have been developed primarily for ␣ L ␤ 2 -integrin (LFA-1, lymphocyte function-associated antigen-1). Here we present the results of screening the Prestwick Chemical Library using a recently developed assay for the detection of ␣ 4 ␤ 1 -integrin allosteric antagonists. Secondary assays confirmed that the compounds identified: 1) do not behave like competitive (direct) antagonists; 2) decrease ligand binding affinity for VLA-4 ϳ2 orders of magnitude; 3) exhibit antagonistic properties at low temperature. In a cell based adhesion assay in vitro, the compounds rapidly disrupted cellular aggregates. In accord with reports that VLA-4 antagonists in vivo induce mobilization of hematopoietic progenitors into the peripheral blood, we found that administration of one of the compounds significantly increased the number of colony-forming units in mice. This effect was comparable to AMD3100, a well known progenitor mobilizing agent. Because all the identified compounds are structurally related, previously used, or currently marketed drugs, this result opens a range of therapeutic possibilities for VLA-4-related pathologies.

show abstract

Section: Discussionmentioning

confidence: 99%

Discovery of Very Late Antigen-4 (VLA-4, α4β1 Integrin) Allosteric Antagonists

Chigaev

Williams

et al. 2011

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…The severity of these infections can be influenced by the protocol utilized (dosage, frequency, and route of administration). Considering the most used mAbs in clinical practice, the reported infectious complications remain low in frequency, and are limited mainly to mAbs targeting antigens such as CD52, CD20, tumour necrosis factor (TNF)-a, and the integrin very late antigen (VLA)-4 [2]. Besides bacterial and fungal infections, viral infections/reactivations are important factors limiting the utilization of biological agents (Table 1).…”

Section: Introductionmentioning

confidence: 99%

The laboratory of clinical virology in monitoring patients undergoing monoclonal antibody therapy

Cavallo

2011

Clinical Microbiology and Infection

View full text Add to dashboard Cite

The relevant efficacy of monoclonal antibodies (mAbs) has resulted in the successful treatment of several diseases, although susceptibility to infections remains a major problem. This review summarizes aspects of the literature regarding viral infections and mAbs, specifically addressing the risk of infection/reactivation, the measures that can reduce this risk, and the role played by the laboratory of clinical virology in monitoring patients undergoing mAb therapy.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2010

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Les complications infectieuses liées à l’utilisation des anticorps monoclonaux chez l’homme

Cited by 5 publications

References 32 publications

Discovery of Very Late Antigen-4 (VLA-4, α4β1 Integrin) Allosteric Antagonists

Discovery of Very Late Antigen-4 (VLA-4, α4β1 Integrin) Allosteric Antagonists

The laboratory of clinical virology in monitoring patients undergoing monoclonal antibody therapy

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About